aTyr Pharma (LIFE) Tops Q4 EPS by 35c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. FIX
9. TSCO
10. BE

Go back to aTyr Pharma (LIFE) Tops Q4 EPS by 35c

aTyr Pharma Announces Fourth Quarter and Full Year 2020 Results and Provides Corporate Update

March 23, 2021 4:05 PM EDT

Completed enrollment of ATYR1923 clinical trial in patients with pulmonary sarcoidosis. Data is expected in the third quarter.

Results from ATYR1923 clinical trial in patients with COVID-19 severe respiratory complications demonstrated favorable safety profile and signals of activity based on clinical readouts and inflammatory biomarkers.

COVID-19 findings provided first-in-patient mechanistic proof-of-concept for ATYR1923.

Company to host conference call and webcast today, March 23, at 5:00 p.m. EDT / 2:00 p.m. PDT.

SAN DIEGO, March 23, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.... More